Mereo BioPharma (MREO) Total Debt (2017 - 2024)

Mereo BioPharma (MREO) has reported Total Debt for 8 consecutive years, with $5.5 million the latest figure, recorded in Q4 2024.

• On a quarterly basis, Total Debt changed N/A year-over-year to $5.5 million in Q4 2024; TTM through Dec 2024 was $5.5 million, a N/A change from a year earlier, with the FY2024 full-year figure at $5.5 million, changed N/A from the prior year.
• Total Debt was $5.5 million for Q4 2024 at Mereo BioPharma, roughly flat from $5.6 million in the prior quarter.
• Over five years, Total Debt peaked at $50.9 million in Q2 2020 and troughed at $4.6 million in Q1 2024.
• A 5-year average of $18.0 million and a median of $19.4 million in 2021 frame the typical range for Total Debt.
• Across the five-year window, Total Debt jumped 42.71% in 2020 and sank 67.26% in 2024, its largest moves.
• Over 5 years, Total Debt stood at $21.3 million in 2020, then decreased by 9.03% to $19.4 million in 2021, then jumped by 34.11% to $26.0 million in 2022, then slumped by 42.08% to $15.1 million in 2023, then sank by 63.25% to $5.5 million in 2024.
• The last three Total Debt figures came in at $5.5 million (Q4 2024), $5.6 million (Q3 2024), and $4.9 million (Q2 2024), per Business Quant data.